CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - FRA:5CV - NL0015436031 - Common Stock
4.606 EUR
+0.01 (+0.13%)
Overall 5CV gets a fundamental rating of 6 out of 10. We evaluated 5CV against 75 industry peers in the Biotechnology industry. While 5CV has a great health rating, its profitability is only average at the moment. 5CV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
In the past year 5CV had a positive cash flow from operations.
5CV had negative earnings in 4 of the past 5 years.
In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
5CV has a Return On Assets of 28.11%. This is amongst the best in the industry. 5CV outperforms 96.00% of its industry peers.
The Return On Equity of 5CV (33.02%) is better than 96.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 28.35%, 5CV belongs to the top of the industry, outperforming 97.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 5CV (37.93%) is better than 89.33% of its industry peers.
The Operating Margin of 5CV (40.58%) is better than 94.67% of its industry peers.
Looking at the Gross Margin, with a value of 94.81%, 5CV belongs to the top of the industry, outperforming 90.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 5CV is creating value.
The number of shares outstanding for 5CV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 5CV has more shares outstanding
5CV has a better debt/assets ratio than last year.
2.2 Solvency
5CV has an Altman-Z score of 9.55. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 5CV (9.55) is better than 84.00% of its industry peers.
5CV has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
The Debt to FCF ratio of 5CV (0.18) is better than 92.00% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that 5CV is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.05, 5CV is doing good in the industry, outperforming 68.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.55 |
ROIC/WACC3.95
WACC7.18%
2.3 Liquidity
5CV has a Current Ratio of 6.17. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.17, 5CV is doing good in the industry, outperforming 80.00% of the companies in the same industry.
5CV has a Quick Ratio of 6.16. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 5CV (6.16) is better than 82.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 170.16% over the past year.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
Based on estimates for the next years, 5CV will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
5CV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.15% yearly.
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue Next Year-84.63%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.99%
Revenue Next 5Y-11.15%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.29 indicates a rather cheap valuation of 5CV.
Based on the Price/Earnings ratio, 5CV is valued cheaper than 94.67% of the companies in the same industry.
5CV is valuated cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.29 | ||
| Fwd PE | N/A |
4.2 Price Multiples
5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 94.67% of the companies in the same industry.
94.67% of the companies in the same industry are more expensive than 5CV, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.29 | ||
| EV/EBITDA | 3 |
4.3 Compensation for Growth
The decent profitability rating of 5CV may justify a higher PE ratio.
A cheap valuation may be justified as 5CV's earnings are expected to decrease with -31.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
5. Dividend
5.1 Amount
No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (9/12/2025, 7:00:00 PM)
4.606
+0.01 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.6%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.04B
Analysts72.31
Price Target4.2 (-8.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.15%
PT rev (3m)-32.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-549.77%
EPS NY rev (1m)0%
EPS NY rev (3m)8.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.01%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-7.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.29 | ||
| Fwd PE | N/A | ||
| P/S | 2.03 | ||
| P/FCF | 5.29 | ||
| P/OCF | 5.08 | ||
| P/B | 1.77 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 3 |
EPS(TTM)0.87
EY18.89%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.87
FCFY18.91%
OCF(TTM)0.91
OCFY19.68%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.55 |
F-Score9
WACC7.18%
ROIC/WACC3.95
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-84.63%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.99%
Revenue Next 5Y-11.15%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A